Molson Coors doubles down on premium, innovative drinks amid beer demand decline

Company’s innovation efforts include cannabis-infused beverages

Molson Coors Brewing Co. plans to continue focusing on offering more premium and innovative drinks, including a soon-to-be launched line of cannabis-infused beverages, as it grapples with declining beer demand in North America.

“Consumers are drinking slightly less, but better,” said CEO Mark Hunter during a conference call with analysts Tuesday after the company released its fourth-quarter financial results.

The company must accelerate premiumization of its portfolio and innovation agenda, he said.

It’s doubling down on efforts to promote several brands, including Blue Moon — a craft brand that Molson plans to double its media spend on in the United States. The brand is called Belgian Moon in Canada.

Hunter also outlined some of the company’s innovation efforts, including cannabis-infused beverages.

The company expects Truss, a joint venture with Hexo Corp., to launch a portfolio of cannabis-infused beverages this autumn. The federal government has said it will legalize edibles by Oct. 17.

Molson, which keeps its books in U.S. dollars, is over delivering on its cost-savings plans for 2017-19, which is partly insulating the company from weaker industry demand in North America, among other industry challenges, Hunter said.

The company also restated its financial results for 2016 and 2017 due to income tax accounting errors.

For 2016, it understated its deferred tax liability and income tax expense which resulted in an overstatement of its net income by $399.1 million.

However, the deferred tax liability required revaluation in 2017 due to U.S. tax changes and that resulted in an overstatement of its income tax expense and understatement of its net income of $151.4 million for the year.

The company reported a fourth-quarter profit of $76 million or 35 cents per diluted share for the three months ended Dec. 31 compared with a profit of $716.9 million or $3.31 per diluted share a year earlier.

Its underlying profit for the quarter amounted to $182.3 million or 84 cents per diluted share, up from $134.3 million or 62 cents per share a year earlier.

Net sales totalled $2.42 billion, down from $2.58 billion.

Molson Coors shares were down $5.99 or 6.8 per cent at $82.01 in afternoon trading on the Toronto Stock Exchange.

Just Posted

Holidays can be stressful enough without a visit from the fire department

The Castor Volunteer Fire Department is made up of around 18 members

Lacombe resident to establish scholarship to help kids in Uganda

‘Through the Eyes of the Children’ to help four orphaned children in Africa

‘You can take the kid from the farm, but you can’t take the farm from the kid!’

Former area resident Maxine Berry reflects on growing up years in Endiang region

Red Deer-Lacombe MP, other Conservative MPs meet with AB justice minister

Calkins said the justice system is a revolving door for criminals targeting rural areas

Lighting up a Stettler neighbourhood for a terrific cause

Every year, the Maruk family puts up an amazing Christmas lights show

Fashion Fridays: A masterclass on H&M knitwear

Kim XO, helps to keep you looking good on Fashion Fridays on the Black Press Media Network

‘He was good for the West:’ Sadness, surprise in Saskatchewan over Scheer

Saskatchewan Premier Scott Moe and his predecessor, Brad Wall, both thanked Andrew Scheer

Travellers know little about air-passenger rights, Canadian poll suggests

The first set of passenger-rights rules landed in mid-July and the rest this weekend

Johnson claims Brexit mandate with new conservative majority

Conservative Party wins 365 seats in the House of Commons

Couple who bought $120k banana duct-taped to wall say artwork will be ‘iconic’

Pair compared it to Warhol’s ‘Campbell’s Soup Cans,’ which was initially ‘met with mockery’

Alberta to change drug coverage for 26,000 patients, expects to save up to $380M

Patients being treated with biologics on government-sponsored drug plans must switch to biosimilars

Race to replace Andrew Scheer could be a crowded one

Many familiar faces, such as Maxime Bernier, Jason Kenney, Doug Ford and Kevin O’Leary, have said no

Most Read